Condition: Fetal Growth Retardation · Intrauterine Growth Restriction · Sponsor: Institut d'Investigacions Biomèdiques August Pi i Sunyer
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
This description comes directly from the study's public registry record.
Elisenda Eixarch, MD; PhD · 0034 932279333 · eixarch@clinic.cat
Elena Monterde, MD · 0034 932279333 · monterde@clinic.cat
Always discuss trial participation with your own doctor first.
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Spain | Recruiting |
| Hospital del Mar | Barcelona, Spain | Recruiting |
| Hospital Dexeus-Quirón | Barcelona, Spain | Recruiting |
| Hospital Sant Joan de Déu | Esplugues de Llobregat, Spain | Recruiting |
| Hospital General del Hospitalet | L'Hospitalet de Llobregat, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05038462